3420
Pharmacy reimbursement and pharmacoeconomic aspects of therapy of bronchial asthma
Bronchial asthma (BA) is an urgent public health problem. Treatment of asthma is based on the level of disease control. The change in the structure of basic therapy
and the replacement of inhalers are the main causes of exacerbations of asthma and an increase in material costs. «Symbicort Maintenance And Reliever Therapy»
(SMART) promote effective control of asthma: providing monitoring and decrease future risk of exacerbation. Improving control of asthma will reduce the steroid
load, to reduce the number of hospitalizations and the number of ambulance calls.
Key words: bronchial asthma, preferential provision of medicines, combined basic therapy, efficiency
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Leshchenko I.V. Pharmacy reimbursement and pharmacoeconomic aspects of therapy of bronchial asthma // Pharmacoeconomics: theory and practice. - 2018. - Vol.6, №1. - P.21-25 DOI: https://doi.org/10.30809/phe.1.2018.4
Comments0